Stents kommen zum Einsatz, um Verengungen von Blutgefäßen zu beseitigen, das Gefäß zu stabilisieren und damit Schlaganfällen und Herzinfarkten vorzubeugen. Das Implantieren schädigt jedoch die Gefäßinnenwand, zudem wird ein körperfremdes Material in den Körper eingesetzt. Beides kann zu einer erneuten Verengung des betroffenen Blutgefäßes beitragen. Forscher des Fraunhofer IAP wollen das verhindern – mit speziell beschichteten und sich auflösenden Stents.

Both randomised clinical trials demonstrated positive outcomes that met primary endpoints for the Selution SLR drug-eluting balloon (DEB) compared to the current standard of care in treating de novo and in-stent restenosis (ISR) coronary lesions. The results highlight Selution as an alternative to drug-eluting stents (DES), offering physicians the ability to minimise the need for stents, the company said in a press release highlighting the results.

A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI). These breakthrough findings of an international clinical trial led by a Mount Sinai researcher could transform the way this patient population is treated.

“Endovascular thrombectomy has transformed acute ischaemic stroke care, with onset-to-puncture [OTP] time widely recognised as a critical determinant of outcome,” the authors write, outlining the backdrop to their study. “However, emerging evidence suggests that in-hospital procedure time—from arterial puncture to final recanalisation—may have an equally or more significant impact.”

Face à la possible suppression du remboursement des stents, plusieurs praticiens du CNCH ont récemment alerté sur les conséquences majeures de cette mesure. Pour rappel, les stents sont des dispositifs médicaux implantés dans les artères et sont facturés en sus du tarif du GHS. La réforme envisagée prévoit d’intégrer le coût des stents directement dans le tarif des GHS, ce qui entraînerait la suppression de leur remboursement spécifique. 

Le ministère de la Santé prévoit de nouvelles économies sur les dispositifs médicaux à hauteur de 160 millions d’euros, en particulier dans le domaine du cardio-vasculaire. Les industriels sont vent debout.

For patients with compromised limb viability, such as acute and chronic limb-threatening ischaemia, or severe functional impairment that does not improve with exercise training, lower extremity revascularization is recommended. Given the complexity of PAD management, a multidisciplinary vascular team is required to achieve the best individualized treatment. Further research efforts should focus on reducing ischaemic events and health disparities and on optimizing the implementation of GDMT and exercise therapy, as well as improving the quality of life in patients with PAD.

This consensus sought to standardize study designs and endpoints for clinical trials involving drug-coated balloons, including defining angiographic, intravascular, and non-invasive imaging methods for lesion assessment, alongside considerations for post-revascularization pharmaco-therapy. The concept of ‘blended therapy’, which advocates for combining device strategies, is also discussed. This paper delineates study types, endpoint definitions, follow-up protocols, and analytical approaches, aiming to provide consistency and guidance for interventional cardiologists and trialists.

CD47-VE-Cadherin-Mfp-5 (CD47-VE-M) fusion protein was synthesized for the first time. CD47-VE-M coatings promote endothelial repair, suppress macrophage phagocytosis in vitro. Dual-functional stent accelerates endothelialization and reduces restenosis in vivo.

Serruys discusses results of the TRANSFORM-1 study*, where it was shown that after treatment using the SeQuent® Please NEO (B. Braun), a paclitaxel DCB, dissection volume was not associated with late lumen loss, showing in fact an association with late luminal gain. “The more you dissect, the better the result is in the long-term, which is a bit counterintuitive because we were always afraid of dissections previously,” says Serruys.

The duration of dual antiplatelet therapy (DAPT) in patients with myocardial infarction (MI) should be shortened from 1 year to 3 months, according to data from a new randomized, real-world trial. In the DUAL-ACS trial, giving DAPT for the first 3 months after MI and then continuing with single antiplatelet therapy was associated with a strong trend towards lower all-cause mortality than continuing with DAPT for 12 months.  The principal secondary endpoint, cardiovascular death or recurrent MI, did not differ between the two groups, but researchers observed a strong trend towards an increase in major bleeding in patients who received 12 months of DAPT. Unfortunately, the trial was underpowered due to recruitment issues during the COVID-19 pandemic, and none of the results reached significance.

Overall, considerably more success has been achieved in reducing the thrombogenicity of bio-artificial surfaces than in controlling complement activation: For example, surfaces coated with different forms of heparin or PEG are associated with low or negligible activation of coagulation and subsequent platelet loss. Thus, there are numerous surfaces that have low thrombogenicity available that still bear substantial complement-activating capacity. Some of these materials will no doubt be a

This randomised trial will assess a dual-device strategy involving drug-coated balloon (DCB) angioplasty and drug-eluting stent (DES) implantation against single-device approaches using either DCB or DES alone.The study will focus on diabetic patients with de novo coronary artery lesions while addressing a gap in treatment, as these patients often face higher rates of stent failure despite advancements in DES technology.

Technological advances have revolutionized the design, development, and manufacturing of advanced implantable CV devices. However, due to insufficient hemocompatibility, they are still associated with devastating complications. Tissue engineering is an emerging field in contemporary health sciences aimed to optimize CV implants. This scope can be achieved through physical or biochemical surface modification of CV implants aimed to mimicking the physiological endothelial tissue function. The biochemical functionalization described above is difficult from economic and regulatory aspects. Microengineering of CV surface topography can be a promising cost-effective strategy.

TraceLink, the end-to-end digital network platform for intelligent orchestration of the life sciences and healthcare supply chain, has announced significant new platform enhancements to drive supply chain transformation with its Orchestration Platform for Universal Solutions (OPUS). The new capabilities are designed to empower supply chain, finance, commercial, and IT leaders to master today’s supply chain complexities and prepare for the increasing prevalence of goal-oriented AI systems.

Given the growing strength of the evidence that the benefit-to-risk ratio of antiplatelet therapy following myocardial infarction differs markedly by the variables that increase risk for recurrent thrombosis or bleeding, Bhatt believes that risk scoring strategies will be used increasingly. Rather than “eyeballing” risk factors, he called for an objective approach to match patients to an antiplatelet strategy with an optimal projected balance of benefit to risk.

Central airway stenosis, otherwise defined as airway narrowing, is often associated with prolonged intubation, tracheostomy, stenting, tuberculosis or lung transplant. There are approximately 100,000 tracheo-bronchial stenting and dilation procedures performed annually within the United States. The study will serve as the basis for Airiver Medical’s regulatory submission to the FDA and eventual commercialization of the Airiver Pulmonary DCB in the U.S.

Over a century of progress in surgery, drugs, prevention, and emergency response has driven down death rates from heart disease and stroke.

Concept Medical has announced the enrolment of the first patient in the MAGICAL-SV trial, a US investigational device exemption (IDE) study evaluating its MagicTouch sirolimus-coated balloon (SCB) for the treatment of small coronary vessels, following US Food and Drug Administration (FDA) IDE approval.

While stent length mismatch is much more common and taken less seriously,diameter mismatch can be more problematic since it looks strikingly odd & ugly .Still, one section of cardiologists believes a little amount of oversizing is safe and good. There is equal opposition to this concept as well. It is not surprising , acquired stent-ectasia of coronary artery during PCI ,has both advantages as well as troubling issues.